


| | | | |
|---|--------|--|------------------------------|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/765,111 | ATTY. DOCKET NO.: B0801/7196 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  | | FILING DATE: January 18, 2001 | |
| | | APPLICANT: Jonathan A. Fletcher et al. | |
| | | GROUP ART UNIT: Not yet assigned | EXAMINER: Not yet assigned |
| Sheet | 1 of 4 | | |

U.S. PATENT DOCUMENTS

| Examiner's Initials# | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYY |
|----------------------|----------|----------------------|-----------|---|---|
| | | Number | Kind Code | | |
| SP | A1 | 4,444,779 | | Kawamatsu, et al. | 04/24/84 |
| | A2 | 5,686,596 | | Mukherjee | 11/11/97 |
| | A3 | 5,696,104 | | Demarchez, et al. | 12/09/97 |
| | A4 | 5,730,975 | | Hotamisliligil, et al. | 03/24/98 |
| | A5 | 5,747,250 | | Gruss, et al. | 05/05/98 |
| | A6 | 5,814,647 | | Urban, et al. | 09/29/98 |
| | A7 | 5,861,274 | | Evans, et al. | 01/19/99 |
| | A8 | 5,902,726 | | Kliwer, et al. | 05/11/99 |
| | A9 | 5,925,657 | | Seed, et al. | 07/20/99 |
| | A10 | 5,968,960 | | Schwartz | 10/19/99 |

FOREIGN PATENT DOCUMENTS


| Examiner's Initials# | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|----------------------|----------|-------------------------|----------|-----------|---|--|-------------------|
| | | Office/Country | Number | Kind Code | | | |
| SP | B1 | WO | 95/10271 | | | 04/20/95 | |
| | B2 | WO | 95/35108 | | | 12/28/95 | |
| | B3 | WO | 96/33724 | | | 10/31/96 | |
| | B4 | WO | 96/34943 | | | 11/07/96 | |
| | B5 | WO | 97/17091 | | | 05/15/97 | |
| | B6 | WO | 98/25598 | | | 06/18/98 | |

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials# | Cite No | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|----------------------|---------|---|-------------------|
| SP | C1 | POLEEV, Andrej et al., "Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors," <i>Eur. J. Biochem.</i> , 1995, Vol. 228, pp. 899-911 | |
| | C2 | MAULBECKER, Catharina C. et al., "The oncogenic potential of Pax genes," <i>The EMBO Journal</i> , 1993, Vol. 12, No. 6, pp. 2361-2367 | |
| | C3 | MOTOJIMA K., "Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions," <i>Cell Struct Funct.</i> , Oct. 1993, 18(5):267-77 - Abstract | |
| | C4 | BOGAZZI, F. et al., "A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor," <i>J. Biol. Chem.</i> , April 22, 1994, 269(16):11683-6 - Abstract | |
| | C5 | TELL, G. et al., "structural defects of a Pax8 mutant that give rise to congenital hypothyroidism," <i>Biochem. J.</i> , July 1, 1999, 341 (Pt 1):89-93 - Abstract | |
| | C6 | MACCHIA, P.E. et al., "PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis," <i>Nat. Genet.</i> , May 1998, 19(1):83-6 - Abstract | |
| | C7 | DAMANTE, G., "Thyroid defects due to Pax8 gene mutations," <i>Eur. J. Endocrinol.</i> , Dec. 1998, 139(6):563-6 | |
| | C8 | POLEEV, A. et al., "Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors," <i>Eur. J. Biochem.</i> , March 15, 1995, 228(3):899-911 - Abstract | |

| | | | | |
|--|-----|---|--|--|
| <div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block; text-align: center;"> <p>OFFICE</p> <p>APR 28 2001</p> <p>TRADEMARK OFFICE</p> </div> | C9 | POLEEV, A. et al., "PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors," <i>Development</i> , Nov. 1992, 116(3):611-23 – Abstract | | |
| | C10 | PLACHOV, D. et al., "Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland," <i>Development</i> , Oct. 1990, 110(2):643-51 – Abstract | | |
| | C11 | KOZMIK, Z. et al., "Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties," <i>Mol. Cell Biol.</i> , Oct. 1993, 13(10):6024-35 – Abstract | | |
| | C12 | PERALDI, P. et al., "Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling," <i>J. Clin. Invest.</i> , Oct. 1, 1997, 100(7):1863-9 – Abstract | | |
| | C13 | DEVCHAND, P.R. et al., "Chemical probes that differentially modulate peroxisome proliferator-activated receptor alpha and BLTR, nuclear and cell surface receptors for leukotriene B(4)," <i>J. Biol. Chem.</i> , Aug. 13, 1999, 274(33):23341-8 – Abstract | | |
| | C14 | TONTONOZ, P. et al., "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor," <i>Medical Sciences</i> , Jan. 1997, Vol. 94, pp. 237-241 | | |
| | C15 | KUBOTA, Tetsuya et al., "Ligand for Peroxisome Proliferator-activated Receptor γ (Troglitazone) Has Potent Antitumor Effect against Human Prostate Cancer Both <i>in Vitro</i> and <i>in Vivo</i> ," <i>Cancer Research</i> , August 1, 1998, Vol. 58, pp. 3344-3352 | | |
| | C16 | Editorial, "PPAR-the good news and the bad," <i>Nature Medicine</i> , Sept. 1998, Vol. 4, No. 9, pp. 981 | | |
| | C17 | LEFEBVRE, Anne-Marie et al., "Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC ^{min} /+mice," <i>Nature Medicine</i> , Sept. 1998, Vol. 4, No. 9, pp. 1053-1057 | | |
| | C18 | SAEZ, Enrique et al., "Activators of the nuclear receptor PPAR γ enhance colon polyp formation," <i>Nature Medicine</i> , Sept. 1998, Vol. 4, No. 9, pp. 1058-1061 | | |
| | C19 | MUELLER, Elisabetta et al., "Terminal Differentiation of Human Breast Cancer through PPAR γ ," <i>Molecular Cell</i> , February 1998, Vol. 1, pp. 465-470 | | |
| | C20 | SARRAF, Pasha et al., "Loss-of-Function Mutations in PPAR γ Associated with Human Colon Cancer," <i>Molecular Cell</i> , June 1999, Vol. 3(6), pp. 799-804 | | |
| | C21 | SARRAF, Pasha et al., "Differentiation and reversal of malignant changes in colon cancer through PPAR γ , September 1998, Vol. 4, No. 9, pp. 1046-1052 | | |
| | C22 | ELSTNER, Elena et al., "Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells <i>in vitro</i> and in BNX mice," <i>Proc. Natl. Acad. Sci. USA</i> , July 1998, Vol. 95, pp. 8806-8811 | | |
| | C23 | TONG-CHUAN, He et al., "PPAR δ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs," <i>Cell</i> , October 29, 1999, Vol. 99, pp. 335-345 | | |
| | C24 | SEED, Brian, "PPAR γ and colorectal carcinoma: conflicts in a nuclear family," <i>Nature Medicine</i> , September 1998, Vol. 4, No. 9, pp. 1004-1005 | | |
| | C25 | KITAMURA, S. et al., "PPAR γ Inhibits the Expression of c-MET in Human Gastric Cancer Cells through the Suppression of Ets," <i>Biochem. Biophys. Res. Commun.</i> , November 19, 1999, 265(2):453-456 – Abstract | | |
| | C26 | HIRASE, N. et al., "Thiazolidinedione Induces Apoptosis and Monocytic Differentiation in the Promyelocytic Leukemia Cell Line HL60," <i>Oncology</i> , October 1999, 57 Suppl. S2:17-26 – Abstract | | |
| | C27 | TAKAHASHI, N. et al., "Activation of PPAR γ inhibits cell growth and induces apoptosis in human gastric cancer cells," <i>FEBS Lett</i> , July 16, 1999, 455(1-2):135-9 – Abstract | | |
| | C28 | YEE, L.D. et al., "Peroxisome proliferator-activated receptor gamma activation in human breast cancer," <i>Int. J. Oncol.</i> , November 1999, 15(5):967-73 – Abstract | | |
| | C29 | ASOU, H. et al., "Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids," <i>Int. J. Oncol.</i> , November 1999, 15(5):1027-31 – Abstract | | |
| | C30 | KUBOTA, T. et al., "Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both <i>in vitro</i> and <i>in vivo</i> ," <i>Cancer Res.</i> , August 1, 1998, 58(15):3344-52 – Abstract | | |
| | C31 | ELSTNER, E. et al., "Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells <i>in vitro</i> and in BNX mice," <i>Proc. Natl. Acad. Sci. USA</i> , July 21, 1998, 95(15):8806-11 – Abstract | | |
| | C32 | LEFEBVRE, A.M. et al., "Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC ^{Min} /+mice," <i>Nat. Med.</i> , September 1998, 4(9):1053-7 – Abstract | | |
| | C33 | SAEZ, E. et al., "Activators of the nuclear receptor PPAR γ enhance colon polyp formation," <i>Nat. Med.</i> , September 1998, 4(9):1058-61 – Abstract | | |
| | C34 | MANSEN, A. et al., "Expression of the peroxisome proliferator-activated receptor (PPAR) in the | | |

| | | | | |
|--|-----|--|--|--|
| | | mouse colonic mucosa," <i>Biochem. Biophys. Res. Commun.</i> , May 24, 1996, 222(3):844-51 - Abstract | | |
| | C35 | BROCKMAN, J.A. et al., "Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells, <i>Gastroenterology</i> , November 1999, 115(5):1049-55 | | |
| | C36 | DuBOISE, R.N. et al., "The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers," <i>Carcinogenesis</i> , January 1998, 19(1):49-53 - Abstract | | |
| | C37 | FUJIMURA, S. et al., "Effects of troglitazone on the growth and differentiation of hematopoietic cell lines," <i>Int. J. Oncol.</i> , December 1998, 13(6):1263-7 - Abstract | | |
| | C38 | KITAMURA, S. et al., "Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells," <i>Jpn. J. Cancer Res.</i> , January 1999, 90(1):75-80 - Abstract | | |
| | C39 | DEMETRI, G.D. et al., "Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma," <i>Proc. Natl. Acad. Sci. USA</i> , March 30, 1999, 96(7):3951-6 - Abstract | | |
| | C40 | SARRAF, P. et al., "Differentiation and reversal of malignant changes in colon cancer through PPARgamma," <i>Nat. Med.</i> , September 1998, 4(9):1046-52 - Abstract | | |
| | C41 | RICOTE, M. et al., "The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation," <i>Nature</i> , January 1998, 391(6662):79-82 - Abstract | | |
| | C42 | SU, C.G. et al., "A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response," <i>J. Clin. Invest.</i> , August 1999, 104(4):383-9 - Abstract | | |
| | C43 | IJIMA, K. et al., "Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells," <i>Biochem. Biophys. Res. Commun.</i> , June 18, 1998, 247(2):353-6 - Abstract | | |
| | C44 | FORMAN, B.M. et al., "15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma," <i>Cell</i> , December 1, 1995, 83(5):803-12 - Abstract | | |
| | C45 | SCHULMAN, I.G. et al., "Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function," <i>Mol. Cell Biol.</i> , June 1998, 18(6):3483-94 - Abstract | | |
| | C46 | SPIEGELMAN, B.M. et al., "PPAR gamma and the control of adipogenesis," <i>Biochimie</i> , Feb-March 1997, 79(2-3):111-2 - Abstract | | |
| | C47 | FREAKE, H.C., "A genetic mutation in PPAR gamma is associated with enhanced fat cell differentiation: implications for human obesity," <i>Nutr. Rev.</i> , May 1999, 57(5 Pt 1):154-6 - Abstract | | |
| | C48 | GORLA-BAJSZCZAK, A. et al., "Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR," <i>Mol. Cell Endocrinol.</i> , January 25, 1999, 147(1-2):37-47 - Abstract | | |
| | C49 | ROBINSON, C.E. et al., "DNA bending is induced by binding of the peroxisome proliferator-activated receptor gamma 2 heterodimer to its response element in the urine lipoprotein lipase promoter," <i>Biochem. Biophys. Res. Commun.</i> , March 27, 1998, 244(3):671-7 - Abstract | | |
| | C50 | OBERFIELD, J.L. et al., "A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation," <i>Proc. Natl. Acad. Sci. USA</i> , May 25, 1999, 96(11):6102-6 - Abstract | | |
| | C51 | PALMER, C.N. et al., "Peroxisome proliferator activated receptor-alpha expression in human liver," <i>Mol. Pharmacol.</i> , January 1998, 53(1):14-22 - Abstract | | |
| | C52 | GRINDFLEK, E. et al., "Characterisation of porcine peroxisome proliferator-activated receptors gamma 1 and gamma 2: detection of breed and age differences in gene expression," <i>Biochem. Biophys. Res. Commun.</i> , August 28, 1998, 249(3):713-8 - Abstract | | |
| | C53 | SUNDEVOLD, H. et al., "Characterisation of bovine peroxisome proliferator-activated receptors gamma 1 and gamma 2: genetic mapping and differential expression of the two isoforms," <i>Biochem. Biophys. Res. Commun.</i> , October 29, 1997, 239(3):857-61 - Abstract | | |
| | C54 | BRAISSANT, O. et al., "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat," <i>Endocrinology</i> , January 1996, 137(1):354-66 - Abstract | | |
| | C55 | ELBRECHT, A. et al., "Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2," <i>Biochem. Biophys. Res. Commun.</i> , July 16, 1996, 224(2):431-7 - Abstract | | |
| | C56 | WERMAN, A. et al., "Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin," <i>J. Biol. Chem.</i> , August 8, 1997, 272(32):20230-5 - Abstract | | |
| | C57 | WESTIN, S. et al., "Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators," <i>Nature</i> , September 10, 1998, 395(6698):199-202 - Abstract | | |
| | C58 | LEHMANN, J.M. et al., "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome | | |

| | | | | |
|---|-----|---|--|--|
| <div style="text-align: center;">  </div> | | proliferator-activated receptor gamma (PPAR gamma)," <i>J. Biol. Chem.</i> , June 2, 1995, 270(22):12953-6 – Abstract | | |
| | C59 | KLIEWER, S.A. et al., "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," <i>Proc. Natl. Acad. Sci. USA</i> , July 19, 1994, 91(15):7355-9 – Abstract | | |
| | C60 | DiRENZO, J. et al., "Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors," <i>Mol. Cell Biol.</i> , April 1997, 17(4):2166-76 – Abstract | | |
| | C61 | MIZUKAMI, J. et al., "The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP," <i>Biochem. Biophys. Res. Commun.</i> , November 7, 1997, 240(1):61-4 – Abstract | | |
| | C62 | HSU, M.H. et al., "A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding," <i>J. Biol. Chem.</i> , October 23, 1998, 273(43):27988-97 – Abstract | | |
| | C63 | GELMAN, L. et al., "p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively," <i>J. Biol. Chem.</i> , March 19, 1999, 274(12):7681-8 – Abstract | | |
| | C64 | WILSON, T.M. et al., "Peroxisome proliferator-activated receptor agonists," <i>Curr. Opin. Chem. Biol.</i> , August 1997, 1(2):235-41 – Abstract | | |
| | C65 | DOWELL, P. et al., "Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein," <i>J. Biol. Chem.</i> , May 28, 1999, 274(22):15901-7 – Abstract | | |
| | C66 | AUWERX, J. et al., "Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects," <i>J. Atheroscler. Thromb.</i> , 1996, 3(2):81-9 – Abstract | | |
| | C67 | BERGER, J. et al., "Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects," <i>J. Biol. Chem.</i> , March 5, 1999, 274(10):6718-25 – Abstract | | |
| | C68 | WILLSON, T.M. et al., "Discovery of ligands for the nuclear peroxisome proliferator-activated receptors," <i>Ann. N.Y. Acad. Sci.</i> , December 27, 1996, 804:276-83 – Abstract | | |
| | C69 | SPIEGELMAN, B.M., "PPAR-gamma: adipogenic regulator and thiazolidinedione receptor," <i>Diabetes</i> , April 1998, 47(4):507-14 – Abstract | | |
| | C70 | SPENCER, C.M. et al., "Troglitazone," <i>Drugs</i> , July 1997, 54(1):89-101, discussion 102 – Abstract | | |
| | C71 | SHAO, D. et al., "Interdomain communication regulating ligand binding by PPAR-gamma," <i>Nature</i> , November 26, 1998, 396(6709):377-80 – Abstract | | |
| | C72 | NOLTE, R.T. et al., "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma," <i>Nature</i> , September 10, 1998, 395(6698):137-43 – Abstract | | |
| | C73 | SCHOONJANS, K. et al., "Peroxisome proliferator-activated receptors, orphans with ligands and functions," <i>Curr. Opin. Lipidol.</i> , June 1997, 8(3):159-66 – Abstract | | |
| 86 | C74 | LIN, Q. et al., "Ligand selectivity of the peroxisome proliferator-activated receptor alpha," <i>Biochemistry</i> , January 5, 1999, 38(1):185-90 – Abstract | | |

| | |
|-------------------------------|-----------------------------------|
| EXAMINER <i>Gally Gali</i> | DATE CONSIDERED <i>1/30/03</i> |
|-------------------------------|-----------------------------------|

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



RECEIVE

| | | | | | |
|--|---|--|---|---|--|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/765,111 | | ATTY. DOCKET NO.: B0801/7196-B U 4 2002 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: January 18, 2001 | | TECH CENTER 1600/29 | |
| | | APPLICANT: Jonathan A. Fletcher et al. | | | |
| | | GROUP ART UNIT: 1645 | | | |
| Sheet | 1 | of | 1 | EXAMINER: Not yet assigned | |

U.S. PATENT DOCUMENTS

| Examiner's Initials# | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYY |
|-------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials# | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD- YYYY | Translation (Y/N) |
|-------------------------|-------------|-------------------------|--------|--------------|---|--|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | | | | | | | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials# | Cite No | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) | |
|-------------------------|------------|---|----------------------|--|
| SS | C75 | KROLL, T.G., et al, "PAX8-PPAR γ 1 fusion oncogen in human thyroid carcinoma," Science, 2000, Vol. 289, No. 5483, pp. 1357-1360 | | |
| SS | C76 | MUELLER, E., et al, "Effects of ligand activation of peroxisome proliferator-activated receptor- γ in human prostate cancer," Proceedings of the National Academy of Sciences USA, 2000, Vol. 97, No. 20, pp. 10990- 10995 | | |
| SS | C77 | SIDRANSKY, D. "Nucleic acid-based methods for the detection of cancer," Science, 1997, Vol. 278, pp. 1054-1058 | | |

| | |
|-------------------------------|-----------------------------------|
| EXAMINER <i>Sally Sahi</i> | DATE CONSIDERED <i>1/30/03</i> |
|-------------------------------|-----------------------------------|

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]